株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

癌検査/スクリーニング市場の予測:画像・バイオマーカー・放射線・その他

Cancer Testing/Screening Market - Forecast (2020 - 2025)

発行 IndustryARC 商品コード 622599
出版日 ページ情報 英文 112 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.59円で換算しております。
癌検査/スクリーニング市場の予測:画像・バイオマーカー・放射線・その他 Cancer Testing/Screening Market - Forecast (2020 - 2025)
出版日: 2020年03月11日 ページ情報: 英文 112 Pages
概要

当レポートでは、世界の癌検査/スクリーニングの市場を調査し、市場の定義と概要、主要事業者と市場シェア、市場への各種影響因子の分析、バリューチェーン、市場機会・市場ライフサイクルの分析、癌区分・技術・治療区分・地域/主要国別の動向と市場規模の推移と予測、主要企業のプロファイルなどをまとめています。

第1章 市場概要

第2章 エグゼクティブサマリー

第3章 市場環境

  • 市場シェア分析
  • 競合事業者の分析
    • 製品ベンチマーキング
    • エンドユーザーのプロファイル
    • トップ5社の財務分析

第4章 市場影響因子

  • 成長推進因子
  • 成長阻害因子・課題
  • 産業の魅力

第5章 戦略的市場分析

  • バリューチェーン分析
  • 価格分析
  • 市場機会の分析
  • 製品ライフサイクル
  • サプライヤー・流通販売業者

第6章 市場分析・予測:タイプ別

  • イントロダクション
  • 肺癌
  • 血液癌
  • 骨癌
  • 腹部の癌
  • 眼癌
  • 口腔癌
  • 乳癌
  • その他

第7章 市場分析・予測:技術別

  • イントロダクション
  • 画像
  • バイオマーカー
  • 内視鏡検査
  • 放射線
  • その他

第8章 市場分析・予測:治療別

  • イントロダクション
  • 外科手術
  • 放射線
  • ホルモン療法
  • 化学療法
  • 遺伝子治療
  • その他

第9章 市場分析・予測:ステージ別

  • TNM分類
  • ステージ0-4
  • 予後因子
  • その他

第10章 市場分析・予測:男女別

  • 男性
  • 女性

第11章 市場分析・予測:地域別

  • イントロダクション
  • 南北アメリカ
    • 米国
    • カナダ
    • メキシコ
    • ブラジル
    • その他
  • 欧州
    • 英国
    • ドイツ
    • スペイン
    • フランス
    • イタリア
    • その他
  • アジア太平洋
    • 中国
    • 韓国
    • オーストラリア&ニュージーランド
    • 日本
    • インド
    • その他
  • その他の地域
    • 中東・アフリカ

第12章 市場エントロピー

  • 新製品の開発
  • 製品の投入・JV・M&A

第13章 企業プロファイル

  • Dias Orin S.P.A
  • Immunodiagnostic Systems Holdings Plc
  • Epigenomics Ag
  • Techlab, Inc.
  • Genextropy, Inc.
  • Lifecode
  • Genclis Sa
  • Target Discovery
  • Positive Bioscience
  • Celdara Medical, Llc
目次
Product Code: HCR 0078

Cancer Testing/Screening Market Overview:

According to the findings by WHO, the global mortality rate due to cancer in 2018 surged to 9.6 million. The same study states that up to an astonishing 50% of cancer cases could have been prevented with effective and inexpensive programmes in initial diagnosis, screening, treatment, and palliative care. With the annual economic burden of cancer well-exceeding US$1.16 trillion, the demand for medical facilities to detect and control this intricate disease at the earliest is surfacing the global healthcare forum.[1] Owing to this demand, the global cancer testing market or cancer screening market size is estimated to be $123 billion-$133 billion as of 2018 and is growing at a global CAGR of 4.5%-5.5% during the forecast period 2019-2025.

Cancer Testing Market Outlook:

Cancer testing or screening plays an important role in the detection of various types of cancer before the appearance of symptoms. The main aim of cancer testing is to reduce the number of deaths caused by cancer. Early diagnosis can lead to better treatment and a greater lifespan. Some of the cancer prevention testing-screening tests include various medical imaging tests, screening mammography, endoscopy tests, and biopsy tests.

After an acute analysis of the regional market segments, the Americas is figured to be the leading region, encapsulating nearly 50%-55% of the global cancer testing market demand. The sheer affluence can be explained by the fact that alone in the United States, the number of cancer cases registered in 2018 was estimated to be 1,735,350 (1.7 million).[2] Similarly, the Canadian Cancer Society states that about 1 in 2 Canadians will develop cancer in their lifetimes and 1 in 4 will die of the disease.[3] Cancer screening-testing being an expensive medical procedure has found the scope of application in high-income countries only as of right now. However, government support and indigenous technologies from countries such China, India, and Japan is helping the market penetration and mass commercialization. The majority of low-income economies with inaccessible diagnosis and treatment facilities stands out as potential spots to be capitalized upon by the cancer-screening testing market players.

Cancer Screening Market Growth Drivers and Trends:

'Liquid biopsy' is one of the latest technology emerging in the market which would help in early detection of various cancers by scanning for DNA fragments which are shed by tumor cells. Companies such SRBI healthcare, GRAIL Inc., and others are raising funds for early diagnosis of cancer.

In recent years, Next Generation Sequencing (NGS) is being widely used for the detection of various types of cancer. NGS allows simultaneous sequencing of targeted genomic areas in multiple samples to detect mutations. The main advantage of this method is the need of low amount of DNA or RNA.

Swiss startup SOPHiA Genetics has used Artificial Intelligence (AI) that takes raw genome data and studies the molecular profile of a person's cancer to find more personalized treatment options. This technology helps the doctors to understand the cause of cancer and what best treatment can be suggested for the molecular events that are taking place in the body. It is also predicted that AI would be the future of cancer diagnostics.

Research and campaigns run by several organization regarding timely screening and cancer diagnosis are also disrupting the cancer-testing marketplace and progressing it towards broader commercialization. For example- Centers for Disease Control and Prevention campaign 'Screen for Life'. American Cancer Society in 2017 invested $145 million in cancer research, $129 million in prevention information, and $80 million in detection.

Cancer Testing Market

Cancer Screening Market Players Perspective:

Some of the major key players operating in this technological novel and advanced healthcare landscape are Dias Orin S.P.A, Epigenetics Ag, Techlab, Genextropy Inc., M Genomics Ltd, 20/20 GeneSystems, Inc., AB SCIEX, Abbott Laboratories, Abcodia Ltd., and Abingdon Health Ltd.

Cancer Testing Market Research Scope:

The base year of the study is 2018, with forecast done up to 2025. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. It also provides information on unit shipments. These provide the key market participants with the necessary business intelligence and help them understand the future of the cancer testing/screening market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The key areas of focus include the various diagnosis in cancer testing/screening market and their specific advantages.

Cancer Testing/Screening Market Report: Industry Coverage

By Cancer Type: Lung, Blood, Bone, Others

By Technique: Imaging, Endoscopy, Molecular & Genomics Testing

By Stage: TNM, Prognostic Factors, Others

The Cancer Testing/Screening Market report also analyzes the major geographic regions for the market as well as the major countries for the market in these regions. The regions and countries covered in the study include:

North America: The U.S., Canada, Mexico

South America: Brazil, Venezuela, Argentina, Ecuador, Peru, Colombia, Costa Rica

Europe: The U.K., Germany, Italy, France, The Netherlands, Belgium, Spain, Denmark

APAC: China, Japan, Australia, South Korea, India, Taiwan, Malaysia, Hong Kong

Middle East and Africa: Israel, South Africa, Saudi Arabia

1. Cancer Testing/Screening Market - Overview

  • 1.1. Definitions and Scope

2. Cancer Testing/Screening Market - Executive summary

  • 2.1. Market Revenue, Market Size and Key Trends by Company
  • 2.2. Key Trends by type of Application
  • 2.3. Key Trends segmented by Geography

3. Cancer Testing/Screening Market

  • 3.1. Comparative analysis
    • 3.1.1. Product Benchmarking - Top 10 companies
    • 3.1.2. Top 5 Financials Analysis
    • 3.1.3. Market Value split by Top 10 companies
    • 3.1.4. Patent Analysis - Top 10 companies
    • 3.1.5. Pricing Analysis

4. Cancer Testing/Screening Market Forces

  • 4.1. Drivers
  • 4.2. Constraints
  • 4.3. Challenges
  • 4.4. Porters five force model
    • 4.4.1. Bargaining power of suppliers
    • 4.4.2. Bargaining powers of customers
    • 4.4.3. Threat of new entrants
    • 4.4.4. Rivalry among existing players
    • 4.4.5. Threat of substitutes

5. Cancer Testing/Screening Market -Strategic analysis

  • 5.1. Value chain analysis
  • 5.2. Opportunities analysis
  • 5.3. Product life cycle
  • 5.4. Suppliers and distributors Market Share

6. Cancer Testing/Screening Market - By Type (Market Size -$Million / $Billion)

  • 6.1. Market Size and Market Share Analysis
  • 6.2. Application Revenue and Trend Research
  • 6.3. Product Segment Analysis
    • 6.3.1. Introduction
    • 6.3.2. Lung Cancer
    • 6.3.3. Blood Cancer
    • 6.3.4. Bone Cancer
    • 6.3.5. Gall Bladder Cancer
    • 6.3.6. Testicular Cancer
    • 6.3.7. Thyroid Cancer
    • 6.3.8. Kidney Cancer
    • 6.3.9. Liver Cancer
    • 6.3.10. Pancreatic Cancer
    • 6.3.11. Brain Cancer
    • 6.3.12. Abdominal Cancer
    • 6.3.13. Eye Cancer
    • 6.3.14. Mouth Cancer
    • 6.3.15. Breast Cancer
    • 6.3.16. Cervix Cancer
    • 6.3.17. Ovarian Cancer
    • 6.3.16. Others

7. Cancer Testing/Screening Market - By Technique (Market Size -$Million / $Billion)

  • 7.1. Introduction
  • 7.2. Imaging Techniques
    • 7.2.1. CT scan
    • 7.2.2. MRI
    • 7.2.3. X-ray
    • 7.2.4. Nuclear
    • 7.2.5. Ultrasound
    • 7.2.6. Mammography
    • 7.2.7. Others
  • 7.3. Endoscopy procedure
    • 7.3.1. Colonoscopy
    • 7.3.2. Sigmoidoscopy
    • 7.3.3. Others
  • 7.4. Biopsy and cytology tests
    • 7.4.1. Needle biopsy
    • 7.4.2. CT-guided biopsy
    • 7.4.3. Ultrasound-guided biopsy
    • 7.4.4. Bone biopsy
    • 7.4.5.Bone marrow biopsy
    • 7.4.6.Liver biopsy
    • 7.4.7.Kidney biopsy
    • 7.4.8. Aspiration biopsy
    • 7.4.9. Prostate biopsy
    • 7.4.10 Skin biopsy
    • 7.4.11 Surgical biopsy
    • 7.4.12 Others
  • 7.5. Genomic and Molecular tests
    • 7.5.1. Next Generation Sequencing (NGS)
    • 7.5.2. RT- PCR
    • 7.5.3. icroarray techniques
    • 7.5.4. Biomarker testing
    • 7.5.5. Others

8. Cancer Testing/Screening Market - By Stage (Market Size -$Million / $Billion)

  • 8.1. TNM Stages
  • 8.2. Stages 0,1,2,3,4
  • 8.3. Prognostic Factors
  • 8.4. Other Staging Systems

9. Cancer Testing/Screening Market - By Gender (Market Size -$Million / $Billion)

  • 9.1. Men
    • 9.1.1. New Born
    • 9.1.2. Infant
    • 9.1.3. Child
    • 9.1.4. Adolescent
    • 9.1.5. Adults
    • 9.1.6. Seniors
  • 9.2. Women
    • 9.2.1. New Born
    • 9.2.2. Infant
    • 9.2.3. Child
    • 9.2.4. Adolescent
    • 9.2.5. Adults
    • 9.2.6. Seniors

10. Cancer Testing/Screening - By Geography (Market Size -$Million / $Billion)

  • 10.1. Cancer Testing/Screening Market - North America Segment Research
  • 10.2. North America Market Research (Million / $Billion)
    • 10.2.1. Segment type Size and Market Size Analysis
    • 10.2.2. Revenue and Trends
    • 10.2.3. Application Revenue and Trends by type of Application
    • 10.2.4. Company Revenue and Product Analysis
    • 10.2.5. North America Product type and Application Market Size
      • 10.2.5.1. U.S.
      • 10.2.5.2. Canada
      • 10.2.5.3. Mexico
      • 10.2.5.4. Rest of North America
  • 10.3. Cancer Testing/Screening - South America Segment Research
  • 10.4. South America Market Research (Market Size -$Million / $Billion)
    • 10.4.1. Segment type Size and Market Size Analysis
    • 10.4.2. Revenue and Trends
    • 10.4.3. Application Revenue and Trends by type of Application
    • 10.4.4. Company Revenue and Product Analysis
    • 10.4.5. South America Product type and Application Market Size
      • 10.4.5.1. Brazil
      • 10.4.5.2. Venezuela
      • 10.4.5.3. Argentina
      • 10.4.5.4. Ecuador
      • 10.4.5.5. Peru
      • 10.4.5.6. Colombia
      • 10.4.5.7. Costa Rica
      • 10.4.5.8. Rest of South America
  • 10.5. Cancer Testing/Screening - Europe Segment Research
  • 10.6. Europe Market Research (Market Size -$Million / $Billion)
    • 10.6.1. Segment type Size and Market Size Analysis
    • 10.6.2. Revenue and Trends
    • 10.6.3. Application Revenue and Trends by type of Application
    • 10.6.4. Company Revenue and Product Analysis
    • 10.6.5. Europe Segment Product type and Application Market Size
      • 10.6.5.1. U.K
      • 10.6.5.2. Germany
      • 10.6.5.3. Italy
      • 10.6.5.4. France
      • 10.6.5.5. Netherlands
      • 10.6.5.6. Belgium
      • 10.6.5.7. Spain
      • 10.6.5.8. Denmark
      • 10.6.5.9. Rest of Europe
  • 10.7. Cancer Testing/Screening - APAC Segment Research
  • 10.8. APAC Market Research (Market Size -$Million / $Billion)
    • 10.8.1. Segment type Size and Market Size Analysis
    • 10.8.2. Revenue and Trends
    • 10.8.3. Application Revenue and Trends by type of Application
    • 10.8.4. Company Revenue and Product Analysis
    • 10.8.5. APAC Segment - Product type and Application Market Size
      • 10.8.5.1. China
      • 10.8.5.2. Australia
      • 10.8.5.3. Japan
      • 10.8.5.4. South Korea
      • 10.8.5.5. India
      • 10.8.5.6. Taiwan
      • 10.8.5.7. Malaysia

11. Cancer Testing/Screening Market - Entropy

  • 11.1. New product launches
  • 11.2. M&A's, collaborations, JVs and partnerships

12. Cancer Testing/Screening Market Company Analysis

  • 12.1. Market Share, Company Revenue, Products, M&A, Developments
  • 12.2. Dias Orin S.P.A
  • 12.3. Epigenetics Ag
  • 12.4. Techlab
  • 12.5. Positive Bioscience
  • 12.6. Genextropy Inc.
  • 12.7. M Genomics Ltd
  • 12.8. 20/20 GeneSystems, Inc.
  • 12.9. AB SCIEX
  • 12.10. Abbott Laboratories
  • 12.11. Abcodia Ltd.
  • 12.12. Company 11
  • 12.13. Company 12
  • 12.14. Company 13 and more

"*Financials would be provided on a best efforts basis for private companies"

13. Cancer Testing/Screening Market -Appendix

  • 13.1. Abbreviations
  • 13.2. Sources